Life Sciences Tools and Services

WUXI BIO

WuXi Biologics Chengdu Base Completed, Targeting GMP Production by End-2026

WuXi Biologics Chengdu Microbial Commercialization Facility Achieves Structural Completion and Arrival of Key Equipment

WuXi Biologics' Three Factories in Wuxi Obtain Korean GMP Certification

WuXi Biologics Reaches Sixth Consecutive Morningstar ESG Leadership Rating

WuXi Biologics Obtains ISO 13485:2016 Certification

CMBI Raises Goal Price for Wuxi Biologics to HKD 39

CICC Raises Profit Forecast for Wuxi Biologics and Maintains 'Outperform' Rating

BofA Securities Downgrades WuXi Biologics' Revenue Forecast and Target Price

WuXi Biologics Approves Granting Restricted Stock Awards to Employees

Nomura Releases Report on Wuxi Biologics' Performance and Forecast

WUXI BIO released FY2025 Q3 earnings on March 24 (BJT), actual revenue HKD 6.47 B, actual EPS HKD 0.3329

WUXI BIO released FY2025 9 Months Earnings on March 24, 2026 (BJT), with actual revenue of HKD 17.25 B and actual EPS of HKD 0.9302

WuXi Biologics reports non-GAAP EPS of ¥1.33, revenue of ¥21.79 million

WUXI BIO released FY2025 earnings on March 24 After-Market (BJT), actual revenue HKD 23.82 B (forecast HKD 24.44 B), actual EPS HKD 1.2685 (forecast HKD 1.2194)

WUXI BIO released FY2025 Q4 earnings on March 24 After-Market (BJT), actual revenue HKD 6.581 B, actual EPS HKD 0.3386

WuXi Biologics Reports 45.3% Increase in Net Profit to RMB 5.733 Billion in 2025 Fiscal Year

WUXI BIO to Release FY2025 Earnings on March 24 After-Market (BJT), Forecast Revenue HKD 25.04 B, EPS HKD 1.2529

WuXi Biologics Signs Strategic Collaboration Agreement with Earendil Labs

Nichi Xia Cheng B-Type Private Plc Issues 84,033,600 Shares to Wuxi Biologics HealthCare Venture

BlackRock Reduces Stake in Wuxi Biologics H-shares to 4.51%

NTES-S

KWAN YONG

PEIJIA-B

REMEGEN

RADIANCE HLDGS

POP MART

BAOZUN-W

ARCHOSAUR GAMES

XIAOCAIYUAN

HEPALINK

02268

WXXWY

02269

159615

588130

513120

513700

159992

LABU

Earendil Labs has announced the successful dosing of the first cohort in a Phase I clinical trial for HXN-1011, a novel biparatopic antibody targeting Thymic Stromal Lymphopoietin (TSLP). This antibody shows high affinity and blocks TSLP receptor interactions, demonstrating potent activity in preclinical studies. The company aims to develop innovative treatments for various immunological disorders, emphasizing their commitment to advancing next-generation biologics therapies.

prnewswire

WUXI XDC

WuXi Biologics

Sanofi

iShares US Pharma

China Southern Hang Seng Biotech ETF(QDII)

Ark Genomic Revolution ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Health Care Select Sector SPDR

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

First Trust NYSE Arca Biotech Index Fd

E Fund CSI 300 Health Care ETF

Huaan Hang Seng Biotech ETF

VG Health

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

SPDR S&P Biotech

Minsheng Royal CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Tianhong CNI BIOMEDICINE ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

iShares Biotechnology ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng Health Care ETF(QDII)

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Guotai CSI Bio-medicine ETF

07:00 ETEarendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

02050

06613

03986

00501

06869

01347

06082

02600

01208

SANHUA(02050) rose 6.84%, with a trading turnover 1.8 Billion HKD, and a year-to-date fell 6.3%. Lens(06613) rose 5.23%, with a trading turnover 779.6 Million HKD, and a year-to-date fell 11.4%. YOFC(06869) fell 12.14%, with a trading turnover 5.0 Billion HKD, and a year-to-date rose 331.3%. HUA HONG SEMI(01347) fell 8.74%, with a trading turnover 7.1 Billion HKD, and a year-to-date rose 56%.

Top Gainers&Losers

SANHUA

Lens

GIGADEVICE

OMNIVISION

YOFC

HUA HONG SEMI

BIREN TECH

CHALCO

Top 5 HK Stock Gainers/Losers (>100B) (5.15)

02509

603259

JPMorgan's report highlights the National Healthcare Security Administration's new plan for the 2026 National Reimbursement Drug List, which allows drugs to apply for NRDL inclusion before formal approval. This change is expected to enhance the commercialization prospects for innovative drug developers in China. The report identifies INNOVENT BIO, WUXI APPTEC, WUXI XDC, and SKB BIO as top picks, benefiting from clearer pricing rules and faster market access for high-priced drugs.

AASTOCKS News

QYUNS-B

WuXi AppTec

WUXI APPTEC

SKB BIO

TEDA BIOMEDICAL

INNOVENT BIO

ICBCCS SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Guotai SSE STAR Brand Name Drug ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

Yesterday, WuXi Biologics' stock price quickly rose to HKD 120, with a trading volume reaching HKD 800 million, indicating active market participation. The MACD daily chart generated a golden cross above the zero line, further confirming the bullish trend in the pharmaceutical technology sector, with strong short-term performance. The current stock price is firmly above key technical levels, suggesting a positive outlook for the future. Amid the wave of pharmaceutical technology development, WuXi Biologics, as an important part of the biopharmaceutical CDMO platform, is actively engaged in new drug varieties and industry chain integration, receiving broad market optimism. Additionally, positive developments in Sino-U.S. trade relations and advancements in COVID-19 drug research provide a more solid foundation for expanding its market share. In terms of technical indicators, after the MACD daily chart showed a golden cross signal, it formed upward support on the moving averages, with significant buying volume and price coordination, and the continued warming of market confidence brings necessary conditions for profitability. However, it is important to note that the market's high valuation carries certain bubble risks, and investors should grasp market rhythms and adjust dynamically in a timely manner. Risk warnings include international legal regulations, global industrial chain arrangements, and vaccine development progress, which will continue to pose threats to its profitability. Market changes are rapid, and investors must base their decisions on well-equipped information to make rational choices. This article only provides technical analysis and market information for reference and does not constitute any investment advice. The market carries uncertainties, and investors should make independent decisions based on their own circumstances

Technical Forecast

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Pre-market trend | WuXi Biologics (2269.HK) 5/11 Pharmaceutical technology sets the direction, initial results in new drug development?

WuXi Biologics has received GMP certification from South Korea's MFDS for three of its manufacturing facilities, enabling commercial production of bispecific antibody therapeutics for biliary tract cancer. The certification confirms the company's compliance with global quality standards and enhances its manufacturing capabilities in the Asia-Pacific region. CEO Dr. Chris Chen emphasized the importance of this certification in supporting clients and accelerating the delivery of innovative biologics. WuXi Biologics operates 15 GMP-certified facilities globally and has a strong track record of regulatory compliance and quality assurance.

02:14 ETWuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics

WuXi Biologics (SEHK:2269) has secured ISO 13485:2016 certification for its medical device quality management system, highlighting its commitment to quality and compliance. The company's share price is currently HK$37.18, with a 1-month return of 6.41% and a year-to-date return of 14.26%. Analysts suggest the stock is undervalued, with a fair value estimate of HK$45.08, indicating a potential 38% intrinsic value gap. The company is positioned for growth in the biologics sector, but faces geopolitical risks that could impact its performance.

Simplywall

A Look At WuXi Biologics (SEHK:2269) Valuation After Securing ISO 13485:2016 Certification

WuXi Biologics has achieved ISO 13485:2016 certification, becoming one of the first in China's drug-device combination products sector to do so. The certification, awarded with zero non-conformities, underscores the company's robust quality management system and compliance capabilities. This achievement reflects WuXi's commitment to delivering safe and reliable end-to-end services in the medical device industry. CEO Dr. Chris Chen emphasized the importance of maintaining high-quality standards to support the development of breakthrough therapies. WuXi Biologics continues to strengthen its sustainability and compliance management systems, holding multiple internationally recognized certifications.

22:39 ETWuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing

Citi has reaffirmed its Buy rating for Wuxi Biologics (Cayman) with a price target of HK$42.00, while the stock closed at HK$35.28. The analyst consensus is a Strong Buy with an average target of HK$45.96, indicating a potential upside of 30.28%. Additionally, Morgan Stanley also maintains a Buy rating with a target of HK$50.00.

Tip Ranks

Citi Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)

WUXI BIO(02269.HK)